BioLineRx (BLRX) Total Liabilities (2010 - 2026)

BioLineRx's Total Liabilities history runs 16 years deep, the most recent figure standing at $17.6 million for Q4 2025.

• In Q4 2025, Total Liabilities fell 30.99% year-over-year to $17.6 million; the TTM figure through Dec 2025 stood at $17.6 million (down 30.99% YoY), while the FY2025 annual figure was $17.6 million, down 30.99% from the prior year.
• Total Liabilities for Q4 2025 stood at $17.6 million, down from $20.3 million in the prior quarter.
• The five-year high for Total Liabilities was $50.7 million in Q4 2023, with the low at $11.3 million in Q2 2022.
• The 5-year median for Total Liabilities is $24.3 million (2024), against an average of $27.0 million.
• The sharpest annual moves came in 2023 and 2025: Total Liabilities soared 236.13% in 2023, then sank 54.18% in 2025.
• BioLineRx's Total Liabilities stood at $13.3 million in 2021, then surged by 91.99% to $25.5 million in 2022, then surged by 98.5% to $50.7 million in 2023, then sank by 49.81% to $25.4 million in 2024, then slumped by 30.99% to $17.6 million in 2025.
• Business Quant data shows BLRX's Total Liabilities at $17.6 million in Q4 2025, $20.3 million in Q3 2025, and $23.2 million in Q2 2025.